Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in ValueEli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value
The 150-year-old drugmaker is the first company in health care to hit the milestone. The 150-year-old drugmaker is the first company in health care to hit the milestone.
Opinion: Trump’s regressive deal on GLP-1s misses the mark for patients like meOpinion: Trump’s regressive deal on GLP-1s misses the mark for patients like me
The U.S. government is finally flexing its negotiating muscle to reduce GLP-1 prices and expand access to these medicines — for weight loss — in federal health programs. President Trump’s much-anticipated “deal” with GLP-1 manufacturers Eli Lilly and Novo Nordisk makes modest steps to expand patient access to the class of GLP-1 medications for the Read More
Q&A: Navigating weight loss—when to consider bariatric surgery after GLP-1 therapyQ&A: Navigating weight loss—when to consider bariatric surgery after GLP-1 therapy
People who have used GLP-1 medications—better known by their brand names like Ozempic, Mounjaro or Wegovy—have likely seen meaningful changes in their health, such as improved blood sugar, lower blood pressure and weight loss. People who have used GLP-1 medications—better known by their brand names like Ozempic, Mounjaro or Wegovy—have likely seen meaningful changes in Read More
I Was a 34-Year-Old New Mom When I Was Diagnosed With Stage IV Breast CancerI Was a 34-Year-Old New Mom When I Was Diagnosed With Stage IV Breast Cancer
WeGotThis.org founder and author Elissa Kalver wants to reframe the conversation around metastatic breast cancer.
Novo Nordisk rolls out lower prices for Ozempic and WegovyNovo Nordisk rolls out lower prices for Ozempic and Wegovy
People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications. People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.
How GLP-1s impact the heart and kidneys of veterans with type 2 diabetesHow GLP-1s impact the heart and kidneys of veterans with type 2 diabetes
Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic and Wegovy) becoming known for their weight-loss effects. Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in Read More
Olivia Munn Meets Breast Cancer Patient Inspired by Her JourneyOlivia Munn Meets Breast Cancer Patient Inspired by Her Journey
Over the past year and a half, Olivia Munn has shared her journey with breast cancer, inspiring women to get screened. TODAY’s Jenna Bush Hager introduces her to Michaela Del Barrio, a woman who is navigating a cancer journey similar to Munn’s.
STAT+: Novo nears release of high-stakes data on Alzheimer’s and GLP-1sSTAT+: Novo nears release of high-stakes data on Alzheimer’s and GLP-1s
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we report on how lawsuits linked to Covid-19 are gaining prominence under the Trump administration. We also await Novo results on GLP-1 effects on Alzheimer’s, and more. The need-to-know this morning Alkermes increased Read More
‘Traumatic wait’ for women facing breast cancer diagnoses’Traumatic wait’ for women facing breast cancer diagnoses
Dr Jilly O’Hagan says she is “hugely concerned” after three patients in her surgery received a late cancer diagnosis.
STAT+: Can GLP-1 drugs treat Alzheimer’s? Novo Nordisk will soon announce key resultsSTAT+: Can GLP-1 drugs treat Alzheimer’s? Novo Nordisk will soon announce key results
Within the next two weeks, Novo Nordisk is expected to announce the results of perhaps the most ambitious studies yet of its blockbuster GLP-1 drug semaglutide — whether the medicine can help slow the progression of Alzheimer’s disease. The Danish company has repeatedly stressed that these are risky studies, since there hasn’t yet been definitive Read More